Literature DB >> 32681268

Deep learning for differentiation of benign and malignant solid liver lesions on ultrasonography.

Ianto Lin Xi1, Jing Wu2, Jing Guan2, Paul J Zhang3, Steven C Horii1, Michael C Soulen1, Zishu Zhang4, Harrison X Bai5.   

Abstract

PURPOSE: The ability to reliably distinguish benign from malignant solid liver lesions on ultrasonography can increase access, decrease costs, and help to better triage patients for biopsy. In this study, we used deep learning to differentiate benign from malignant focal solid liver lesions based on their ultrasound appearance.
METHODS: Among the 596 patients who met the inclusion criteria, there were 911 images of individual liver lesions, of which 535 were malignant and 376 were benign. Our training set contained 660 lesions augmented dynamically during training for a total of 330,000 images; our test set contained 79 images. A neural network with ResNet50 architecture was fine-tuned using pre-trained weights on ImageNet. Non-cystic liver lesions with definite diagnosis by histopathology or MRI were included. Accuracy of the final model was compared with expert interpretation. Two separate datasets were used in training and evaluation, one with all lesions and one with lesions deemed to be of uncertain diagnosis based on the Code Abdomen rating system.
RESULTS: Our model trained on the complete set of all lesions achieved a test accuracy of 0.84 (95% CI 0.74-0.90) compared to expert 1 with a test accuracy of 0.80 (95% CI 0.70-0.87) and expert 2 with a test accuracy of 0.73 (95% CI 0.63-0.82). Our model trained on the uncertain set of lesions achieved a test accuracy of 0.79 (95% CI 0.69-0.87) compared to expert 1 with a test accuracy of 0.70 (95% CI 0.59-0.78) and expert 2 with a test accuracy of 0.66 (95% CI 0.55-0.75). On the uncertain dataset, compared to all experts averaged, the model had higher test accuracy (0.79 vs. 0.68, p = 0.025).
CONCLUSION: Deep learning algorithms proposed in the current study improve differentiation of benign from malignant ultrasound-captured solid liver lesions and perform comparably to expert radiologists. Deep learning tools can potentially be used to improve the accuracy and efficiency of clinical workflows.

Entities:  

Keywords:  Deep learning; Diagnosis; Differential; Liver neoplasms; Ultrasonography

Mesh:

Year:  2021        PMID: 32681268     DOI: 10.1007/s00261-020-02564-w

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  1 in total

1.  Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.

Authors:  M Sherman; K M Peltekian; C Lee
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

  1 in total
  4 in total

1.  Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients.

Authors:  Wei-Bin Zhang; Si-Ze Hou; Yan-Ling Chen; Feng Mao; Yi Dong; Jian-Gang Chen; Wen-Ping Wang
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

2.  Deep learning-based classification of primary bone tumors on radiographs: A preliminary study.

Authors:  Yu He; Ian Pan; Bingting Bao; Kasey Halsey; Marcello Chang; Hui Liu; Shuping Peng; Ronnie A Sebro; Jing Guan; Thomas Yi; Andrew T Delworth; Feyisope Eweje; Lisa J States; Paul J Zhang; Zishu Zhang; Jing Wu; Xianjing Peng; Harrison X Bai
Journal:  EBioMedicine       Date:  2020-11-22       Impact factor: 8.143

3.  Translatability Analysis of National Institutes of Health-Funded Biomedical Research That Applies Artificial Intelligence.

Authors:  Feyisope R Eweje; Suzie Byun; Rajat Chandra; Fengling Hu; Ihab Kamel; Paul Zhang; Zhicheng Jiao; Harrison X Bai
Journal:  JAMA Netw Open       Date:  2022-01-04

Review 4.  Artificial intelligence in liver ultrasound.

Authors:  Liu-Liu Cao; Mei Peng; Xiang Xie; Gong-Quan Chen; Shu-Yan Huang; Jia-Yu Wang; Fan Jiang; Xin-Wu Cui; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.